Furthermore, using the MPTP mouse model of PD, the authors found that DRD2 agonists inhibited NLRP3 inflammasome activation, evidenced by decreased caspase‐1 expression and reduced IL‐1β release in the midbrain of wild‐type mice. This evidence concerns the gene NLRP3 and Parkinson disease.